Currently, we are able to use S-1 with gemcitabine and erlotinib, as well as gemcitabine alone, as first-line therapy for advanced pancreatic cancer. In addition, a clinical trial of FOLFIRINOX is underway in Japan. On the other hand, chemoradiotherapy is considered to be one of the treatments of choice for locally advanced pancreatic cancer. This review summarizes current knowledge about non-surgical treatment for advanced pancreatic cancer, mainly based on the results of recent clinical trials.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 01/12/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/22421761